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B-cell co-receptors: The two-headed antigen
Anthony L. DeFranco
Lymphocytes often recognize antigens using not only
their antigen receptors but also ‘co-receptors’ that bind
other molecules associated with the antigen; the co-
receptors then modulate the response to antigen. This
concept has been used to make chimeric antigens that
are extremely potent inducers of antibody responses.
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The immune response is initiated when an antigen is rec-
ognized by specific lymphocytes. Originally, ‘antigen’ was
viewed as a simple entity that bound directly to lympho-
cyte antigen receptors: the B-cell antigen receptor
complex that includes membrane-bound immunoglobulin,
or the T-cell antigen receptor. It has been clear for a
number of years, however, that conventional T cells rec-
ognize not free antigen, but rather antigen-derived pep-
tides bound to proteins of the major histocompatibility
complex (MHC). Now it is becoming clear that the
antigen interacting with B cells may similarly interact with
other molecules of the immune system that allow the B
cell to gain additional information, affecting its response.
In both T cells and B cells, the complexed antigen can
bind not only the antigen receptor, but also a second cell-
surface receptor referred to as the co-receptor. The com-
plexed antigen brings together the antigen receptor and
the co-receptor, with the result that antigen-receptor sig-
naling events are altered and the cell responds accord-
ingly. This principle has now been used to create antigens
for B cells that are extremely good at stimulating the cells
to generate an antibody response [1].
The ability of lymphocytes to gain important information
about the recognized antigen was first appreciated in the
case of T cells. Conventional T cells generally only
become activated in response to antigen in the form of
peptide-plus-MHC complexes. A key feature of the acti-
vation process is that the T cell can distinguish an MHC-
bound ligand from other ligands because the T cell
expresses cell-surface molecules, CD4 and CD8, which
can bind directly to MHC proteins in domains distinct
from their peptide-binding sites. Thus, the T cell recog-
nizes the antigen as a complex ligand that binds to two of
its cell-surface receptors — the T-cell receptor and either
of two co-receptors, CD4 or CD8 — and brings the two
together. The mechanism by which the T cell senses this
dual interaction is not entirely understood, but one part
of it involves Lck, a tyrosine kinase of the Src family.
Lck is pre-bound to CD4 and CD8 and it phosphorylates
key tyrosines in the cytoplasmic domains of various T-
cell receptor subunits [2]. A distinct tyrosine kinase,
ZAP-70, binds to the phosphorylated T-cell receptor
chains and is then itself activated upon tyrosine phospho-
rylation; Lck is probably responsible for this activating
phosphorylation. Lck also enhances T-cell responses by a
second mechanism that does not require its kinase activ-
ity [3]. In the absence of CD4 or CD8 engagement, the T
cell can still be stimulated, but typically this is much less
efficient. In this case, it may be another Src-family
member, Fyn — small amounts of which are bound
directly to the T-cell receptor — that serves to initiate
the early signaling events.
Until recently, the recognition of antigens by B cells was
thought to be a simpler process, involving only an interac-
tion between an antigen and the membrane immunoglob-
ulin part of the B-cell receptor. But the concept is
emerging that B cells also often recognize antigen in the
form of a complex ligand which brings together the B-cell
receptor and another cell-surface receptor, with important
consequences. For example, it is now clear that if the
antigen activates the complement system of proteins
which, like lymphocytes, target invading pathogens — for
instance, by causing the deposition onto the pathogen of
complement protein C3b and subsequent breakdown
products such as C3d — this not only enhances the overall
immune response but also greatly enhances the response
of the B cell itself. In this way, the adaptive immune
response takes advantage of the ability of the ‘alternative
pathway’ of complement activation to selectively target
foreign entities, such as bacteria and viruses.
A dramatic example of this effect of complement protein
C3d on B-cell activation has been provided by recent
experiments of Dempsey et al. [1]. They created fusion
proteins made up of the antigen chicken egg lysozyme and
one, two, or three copies of C3d, a ligand for complement
receptor 2 (CR2). When mice were immunized with these
fusion proteins, their immune systems were strikingly
more sensitive to the chimeric antigen than to lysozyme
alone. Addition of one C3d moiety to the antigen resulted
in 10-fold less antigen being needed to give rise to an
equivalent antibody response; addition of two C3d moi-
eties made the animals 100-fold more sensitive; and addi-
tion of three tandem C3d units made the animals
approximately 1 000-fold more sensitive. This final fusion
protein was an extremely effective antigen, even in the
absence of conventional adjuvants, which are normally
required to enhance the immune response to antigens: the
response to this protein injected in saline was superior to
that of lysozyme injected in complete Freund’s adjuvant.
The ability of the fusion proteins to bring CR2 together
with the B-cell receptor in the B-cell membrane is likely
to be responsible for their impressive efficacy as antigens.
The authors found that the fusion proteins were also more
potent at inducing B-cell receptor signal transduction
events. This result is consistent with earlier work in which
cross-linking of CR2 with the B-cell receptor was found to
enhance B-cell proliferation and signaling [4]. CR2 is
present on the B-cell surface as a complex with other pro-
teins: either complement receptor 1, or CD19, TAPA-1
(CD81) and Leu 13 [5]. Of these, CD19 appears to be pri-
marily responsible for boosting signaling by the B-cell
receptor, as co-cross-linking CD19 with the B-cell recep-
tor potently enhances B-cell receptor signaling and B-cell
proliferation, whereas co-cross-linking with other compo-
nents of the CR2 complex is less effective [4]. The impor-
tance of CD19 is emphasized by the observation that B
cells from mice lacking CD19, as a result of targeted dis-
ruption of the CD19 gene, have clear defects in their anti-
body responses, particularly to T-cell-dependent antigens
[6,7]. Thus, the CR2/CD19 complex of B cells behaves
like the CD4 and CD8 co-receptors of T cells in greatly
boosting responses to antigen.
Two features of CD19 suggest possible mechanisms by
which it could enhance B-cell receptor signaling (Fig. 1).
Firstly, in human B cells, CD19 has been found to associ-
ate with Src-family tyrosine kinases, especially Lyn [8,9].
Thus, CD19 could enhance B-cell receptor signaling by a
mechanism analogous to the primary mechanism by which
CD4 and CD8 are thought to enhance T-cell receptor sig-
naling upon engagement of peptide-plus-MHC ligands. In
addition, B-cell receptor signaling induces prominent tyro-
sine phosphorylation of the cytoplasmic domain of CD19.
This cytoplasmic domain has nine tyrosines, some or all of
which may serve as phosphorylation-regulated binding
sites for signaling components containing Src-homology 2
(SH2) phosphotyrosine-binding domains [4]. Indeed, two
important signaling components, phosphatidylinositol 3-
kinase and Vav have been shown to bind to the cytoplas-
mic domain of CD19 after stimulation [10,11].
So, antigens decorated with complement components serve
to bring together the B-cell receptor and the CR2/CD19 co-
receptor complex, and in this way greatly stimulate B-cell
receptor signaling events. The B cell is also equipped to
recognize a second type of complex ligand: an antigen
molecule decorated with immunoglobulin G (IgG). This
type of complex ligand brings together the B-cell receptor
and FcgRIIB, a receptor for the constant part of IgG. In
this case, rather than potentiating B-cell receptor signal-
ing, the complex ligand attenuates it and so inhibits B-cell
activation. Presumably, this phenomenon is advantageous
to the immune system because antigen–antibody com-
plexes accumulate at a stage in the immune response
when ample specific antibody has already been made and
there is little need for resting B cells to become activated
to produce more antibody. Co-engagement of FcgRIIB
and the B-cell receptor interferes with B-cell receptor sig-
naling by inducing the phosphorylation of a key tyrosine of
the FcgRIIB cytoplasmic domain; once phosphorylated,
this tyrosine serves as a binding site for the SH2-contain-
ing tyrosine phosphatase SHP (also known as PTP-1C and
HCP) [12]. Presumably this phosphorylation is performed
by a tyrosine kinase associating with the B-cell receptor,
either a Src-family member (such as Lyn), or Syk, the B-
cell homolog of ZAP-70. The key targets of SHP phos-
phatase action leading to decreased B-cell receptor
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Figure 1
Possible mechanisms for the co-receptor function of the CR2/CD19
complex in B cells. The co-receptor complex may function analogously
to CD4 and CD8 in T cells, as it has been reported that CD19
associates with Src-family tyrosine kinases such as Lyn. According to
this hypothesis, a complexed antigen or an artificial version of one, as
used by Dempsey et al. [1] (as shown), would bring together the B-cell
antigen receptor (BCR) and the CR2/CD19 complex, allowing Lyn to
phosphorylate the B-cell receptor’s cytoplasmic domain tyrosines and
thereby creating binding sites for another tyrosine kinase, Syk. Syk
appears to be activated by tyrosine phosphorylation, so Lyn could be
responsible for activating Syk. Alternatively, the result of bringing
together the B-cell receptor with CR2/CD19 by C3d-complexed
antigen may be that tyrosine kinases bound to the B-cell receptor can
now efficiently phosphorylate some or all of the nine tyrosines in the
cytoplasmic domain of CD19. Some of these phosphorylated tyrosines
serve as binding sites for the signaling components
phosphatidylinositol 3-kinase (PI 3-K) and Vav.
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signaling and B-cell activation are not known at present.
Nonetheless, what is clear is that B cells, like T cells, often
see antigen not as a simple ligand for their antigen recep-
tors, but rather as part of a complex with other immune
system molecules that engage co-receptors and bring them
together with the antigen receptors, with profound conse-
quences for the response of the lymphocyte.
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